688091.SS
688091.SS
CNE1000050F4
SHANGHAI YIZHONG PHARMACEUTICAL
Loading chart...

Company Profile

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the research and development of anti-tumor drugs and related products in China. The company offers paclitaxel polymer micelles for injection for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, and gynecological tumors. Shanghai Yizhong Pharmaceutical Co., Ltd. was founded in 2009 and is headquartered in Shanghai, China.

Related stocks

002907.SZ
002907.SZ • China
PHARSCIN PHARMA
15.44 CNY
964.79M USD 1Y -4.9%
600422.SS
600422.SS • China
KPC PHARMACEUTICALS INC
8.36 CNY
946.93M USD 1Y -40.3%
600488.SS
600488.SS • China
TIANJIN TIANYAO PHARMACEUTICAL
6.47 CNY
1.06B USD 1Y +59%
603538.SS
603538.SS • China
NINGBO MENOVO PHARMACEUTICAL CO
28.45 CNY
1.45B USD 1Y +80%
002020.SZ
002020.SZ • China
JINGXIN
11.87 CNY
1.53B USD 1Y -41.5%
002038.SZ
002038.SZ • China
SL PHARM
5.76 CNY
885.46M USD 1Y -20.3%
300705.SZ
300705.SZ • China
JIUDIAN
11.23 CNY
840.68M USD 1Y -34%
002550.SZ
002550.SZ • China
QIANHONG BIO-PHARMA
6.52 CNY
1.25B USD 1Y -28.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
61.0% p.a.
Max Drawdown (5Y)
-79.1%
Sharpe Ratio (5Y)
0.13
Beta Factor
-0.44
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 108.2 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (61.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -79.1% in the extended horizon.
ende